Eldelumab
≈ 1 min read
Names in other languages
- العربيةإلديلوماب
- EnglishEldelumab
- ItalianoEldelumab
- فارسیالدلوماب
- 中文埃迪鲁单抗
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Eldelumab (alternative identifier BMS-936557 ) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis. This drug was developed by Bristol-Myers Squibb and Medarex.
Eldelumab (alternative identifier BMS-936557 ) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis. This drug was developed by Bristol-Myers Squibb and Medarex.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1187917134 under CC BY-SA 4.0; modifications have been made.